Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo
Metrics: PDF 813 views | HTML 1285 views | ?
Wen Xu1,2, Yanyu Bi2, Juan Kong2, Jiqin Zhang2, Biao Wang2, Kesang Li2, Mi Tian2, Xiaorong Pan2, Bizhi Shi2, Jianren Gu2, Hua Jiang2, Xianming Kong3, Zonghai Li2
1Medical School of Fudan University, Shanghai, China
2State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
3Renji Hospital, Medical School of Shanghai Jiaotong University, Shanghai, China
Zonghai Li, e-mail: Zonghaili@shsmu.edu.cn
Hua Jiang, e-mail: Jianghuapy@163.com
Xianming Kong, e-mail: firstname.lastname@example.org
Keywords: EGFRvIII+PTEN– GBM, CH12, rapamycin, STAT5
Received: October 17, 2015 Accepted: February 28, 2016 Published: March 26, 2016
There are still unmet medical needs for the treatment of glioblastoma (GBM), the most frequent and aggressive brain tumor worldwide. EGFRvIII, overexpressed in approximately 30% of GBM, has been regarded as a potential therapeutic target. In this study, we demonstrated that CH12, an anti-EGFRvIII monoclonal antibody, could significantly suppress the growth of EGFRvIII+ GBM in vivo; however, PTEN deficiency in GBM reduced the efficacy of CH12 by attenuating its effect on PI3K/AKT/mTOR pathway. To overcome this problem, CH12 was combined with the mTOR inhibitor rapamycin, leading to a synergistic inhibitory effect on EGFRvIII+PTEN– GBM in vivo. Mechanistically, the synergistic antitumor effect was achieved via attenuating EGFR and PI3K/AKT/mTOR pathway more effectively and reversing the STAT5 activation caused by rapamycin treatment. Moreover, the combination therapy suppressed angiogenesis and induced cancer cell apoptosis more efficiently. Together, these results indicated that CH12 and rapamycin could synergistically suppress the growth of EGFRvIII+PTEN– GBM, which might have a potential clinical application in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.